Sartorius | SRT3 - Selling And Administration Expenses


Sartorius reported EUR221.3M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Moderna USD 173M 135M Mar/2026
Organon & Co USD 433M 34M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Sartorius EUR 221.3M 500K Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025